Oaks v. Largo Bioscience, Inc.

CourtDistrict Court, M.D. Tennessee
DecidedMarch 11, 2022
Docket3:21-cv-00541
StatusUnknown

This text of Oaks v. Largo Bioscience, Inc. (Oaks v. Largo Bioscience, Inc.) is published on Counsel Stack Legal Research, covering District Court, M.D. Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Oaks v. Largo Bioscience, Inc., (M.D. Tenn. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION

JAMES OAKS and ) JULIE DEANN OAKS, ) ) Plaintiffs, ) ) v. ) Case No. 3:21-cv-00541 ) Judge Aleta A. Trauger LARGO BIOSCIENCE, INC. and ) SCOTT McFARLAND, ) ) Defendants. )

MEMORANDUM Before the court is the Motion to Dismiss for Lack of Personal Jurisdiction (Doc. No. 17) filed by defendants Largo Bioscience, Inc. (“Largo”) and its Chief Executive Officer, Scott McFarland. For the reasons set forth herein, the court will grant the motion and dismiss this case without prejudice. I. FACTUAL ALLEGATIONS AND PROCEDURAL HISTORY Plaintiffs James Oaks and Julie Oaks, husband and wife, are residents and citizens of Williamson County, Tennessee. Defendant Largo is a Florida corporation with its principal place of business in Largo, Florida. McFarland is domiciled in Olney, Maryland. (Compl., Doc. No. 1 ¶¶ 1–3.) In their Complaint, the plaintiffs allege, generally, that Largo manufactures and sells a product, “Lyme-N,” “throughout the United States,” including in Tennessee, “as well as online, as a safe and effective product for the treatment of certain medical conditions.” (Id. ¶ 12.) On June 22, 2020, James Oaks contacted Largo to obtain information about using Lyme-N to treat his medical condition. (Id. ¶ 14.) McFarland, acting on behalf of Largo, advised Oaks to purchase Lyme-N. The plaintiffs allege that, pursuant to that advice, Oaks purchased Lyme-N. (Id. ¶¶ 15, 17.) On July 20, 2020, Oaks requested additional information from the defendants about how to use the product. He received a response from the defendants advising him how to use it. (Id. ¶ 18.) He used the product in accordance with the instructions received from the defendants during the

period July 20 through August 9, 2020. (Id. ¶ 19.) However, rather than ameliorating Oaks’ underlying medical condition, Lyme-N allegedly exacerbated it substantially. The plaintiffs claim that Oaks experienced severe side effects from Lyme-N, resulting in hospitalization and surgery. Oaks brings a product liability claim against Largo under Tennessee law, a claim against McFarland for the unauthorized practice of medicine, and a claim against Largo for its vicarious liability for McFarland’s unauthorized practice of medicine. Plaintiff Julie Oaks brings a claim based on loss of consortium. Rather than answering the Complaint, the defendants filed a Motion to Dismiss under Rule 12(b)(2), asserting that the court lacks personal jurisdiction over either defendant. (Doc. No. 17.) In support of their motion, the defendants rely on the Declaration of Scott McFarland, in which

McFarland avers that he himself has never owned real or personal property in Tennessee; has never been domiciled in Tennessee; has never established an office or maintained a place of business in Tennessee; and has never made business trips, attended conferences, or otherwise hosted or attended corporate events in Tennessee. (McFarland Decl., Doc. No. 17-2 ¶ 7(a)–(d).) He states that the only contact he has had with the state of Tennessee was “with Plaintiff James Oaks after he reached out and contacted Largo.” (Id. ¶ 7(e).) Concerning Largo, McFarland states that, prior to James Oaks’ contacting it, Largo had never made any shipments into Tennessee and had never been in contact with anyone in Tennessee. (Id. ¶ 8(a)–(b).) In addition, Largo has never maintained an office in Tennessee or owned real or personal property in Tennessee, and it is not registered to do business in Tennessee. It has never maintained an office in Tennessee, marketed itself or its products in Tennessee, or conducted or participated in business conferences in Tennessee. (Id. ¶ 8(c)–(f).) The plaintiffs filed a Response in Opposition to the Motion to Dismiss and the Affidavit of

James Oaks. (Doc. Nos. 26, 26-1.) Oaks’ Affidavit clarifies some of the allegations in the Complaint and conflicts with others. Oaks avers that he is a physician and that he first heard about Lyme-N in 2019 from another physician, who recommended that he “investigate whether it might help” relieve the “mild” symptoms Mr. Oaks was experiencing. (James Oak Aff., Doc. No. 26-1 ¶¶ 4, 5.) Oaks searched for the product online and located Largo’s website: https://www.lyme- n.com/about-lyme-n/. (Id. ¶ 6.) Oaks avers that Largo “markets and sells [Lyme-N] through this website to practitioners that initially use the website to sign up and then the practitioners retail it to their patients.” (Id. ¶ 7.) He claims that the website is “interactive,” insofar as it “enables persons to ask questions on the web page and receive answers from [Largo’s] personnel.” (Id. ¶ 8.) He himself used the website “to ask for and receive information about Lyme-N.” (Id. ¶ 9.) Oaks had

“additional questions and was able to speak” with Scott McFarland by telephone on two separate occasions. (Id. ¶ 10.) In these telephone conversations, James Oaks informed McFarland that he was a physician in Tennessee. McFarland offered to send Oaks a bottle of Lyme-N “as part of a program that Largo utilizes to get practitioners to recommend it to patients. The first bottle was complimentary.” (Id. ¶¶ 11–12.) Oaks placed his order for this complimentary bottle over the phone, apparently through McFarland, and Largo shipped it to him at his home in Tennessee. (Id. ¶¶ 13–14.) Oaks alleges that, after he had already used the product, he “spoke[] to other persons in Tennessee who informed [him] that they too utilized Lyme-N.” (Id. ¶ 16.) With their Reply (Doc. No. 28), the defendants filed the Supplemental Declaration of Scott McFarland (Doc. No. 28-1). The defendants point out that James Oaks, contrary to the allegation in the Complaint, now states that he did not actually purchase a bottle of Lyme-N (Doc. No. 28, at 2), and McFarland avers that “Largo has never conducted any for profit business in Tennessee”

(Doc. No. 28-1 ¶ 6). He further states that no individuals, practitioners, or known users who live in Tennessee have registered on Largo’s website; Oaks was never given access to the distributor login on Largo’s Lyme-N website; and the Lyme-N website does not allow for individuals to order any products directly from the website, nor does it allow individuals to create accounts without Largo’s express authorization and the issuance of account credentials and passwords. (Id. ¶¶ 7– 10.) Although the plaintiffs characterize Largo’s website as “interactive,” McFarland states that it actually “only contains very basic information about Lyme-N, and it requires that any additional requests, orders, or issues be handled outside of the website.” (Id. ¶ 11.) II. LEGAL STANDARDS Rule 12(b)(2) of the Federal Rules of Civil Procedure authorizes a defendant to file a motion to dismiss for lack of personal jurisdiction. Although the defendant is the moving party on

such a motion, the plaintiff, as the party who invokes the court’s jurisdiction, bears the burden of making a prima facie showing of personal jurisdiction. Intera Corp. v. Henderson, 428 F.3d 605, 615 (6th Cir. 2005). Where, as here, neither party has requested an evidentiary hearing, the plaintiff’s burden is “relatively slight.” MAG IAS Holdings, Inc. v. Schmückle, 854 F.3d 894, 899 (6th Cir. 2017). “To defeat dismissal in this context, [the plaintiff] need make only a prima facie showing that personal jurisdiction exists.” Id. To determine whether the plaintiff has made such a showing, the court considers the pleadings and any affidavits submitted by the parties in the light most favorable to the plaintiff.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
McGee v. International Life Insurance
355 U.S. 220 (Supreme Court, 1957)
Illinois v. Hemi Group LLC
622 F.3d 754 (Seventh Circuit, 2010)
Goodyear Dunlop Tires Operations, S. A. v. Brown
131 S. Ct. 2846 (Supreme Court, 2011)
Dorothy Bearry v. Beech Aircraft Corporation
818 F.2d 370 (Fifth Circuit, 1987)
Kerry Steel, Inc. v. Paragon Industries, Inc.
106 F.3d 147 (Sixth Circuit, 1997)
Neogen Corporation v. Neo Gen Screening, Inc.
282 F.3d 883 (Sixth Circuit, 2002)
Intera Corporation v. George Henderson III
428 F.3d 605 (Sixth Circuit, 2005)
Zippo Manufacturing Co. v. Zippo Dot Com, Inc.
952 F. Supp. 1119 (W.D. Pennsylvania, 1997)
Masada Investment Corp. v. Allen
697 S.W.2d 332 (Tennessee Supreme Court, 1985)
Daimler AG v. Bauman
134 S. Ct. 746 (Supreme Court, 2014)
Nasser Beydoun v. Wataniya Restaurants Holding
768 F.3d 499 (Sixth Circuit, 2014)
MAG IAS Holdings v. Rainer Schm�ckle
854 F.3d 894 (Sixth Circuit, 2017)
Charles Curry v. Revolution Laboratories, LLC
949 F.3d 385 (Seventh Circuit, 2020)

Cite This Page — Counsel Stack

Bluebook (online)
Oaks v. Largo Bioscience, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/oaks-v-largo-bioscience-inc-tnmd-2022.